PD-L1 Expression Is a Prognostic Factor in Patients with Thoracic Esophageal Cancer Treated Without Adjuvant Chemotherapy

被引:30
作者
Wakita, Akiyuki [1 ]
Motoyama, Satoru [1 ]
Nanjo, Hiroshi [2 ]
Sato, Yusuke [1 ]
Yoshino, Kei [1 ]
Sasaki, Tomohiko [1 ]
Kawakita, Yuta [1 ]
Liu, Jiajia [1 ]
Imai, Kazuhiro [1 ]
Saito, Hajime [1 ]
Minamiya, Yoshihiro [1 ]
机构
[1] Akita Univ, Grad Sch Med, Dept Thorac Surg, 1-1-1 Hondo, Akita 0108543, Japan
[2] Akita Univ, Grad Sch Med, Dept Pathol, Akita, Japan
关键词
PD-L1; esophageal cancer; prognosis; immunochemistry; LIGAND; 1; PD-L1; TUMOR-INFILTRATING LYMPHOCYTES; RENAL-CELL CARCINOMA; T-CELLS; PROGRAMMED DEATH-1; POOR-PROGNOSIS; B7; FAMILY; B7-H1; SURVIVAL; MOLECULE;
D O I
10.21873/anticanres.11467
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background/Aim: Programmed death- 1 ligand 1 (PD-L1) induces apoptosis of tumor-reactive T-cells, that enables tumors to evade immune defense and thus furthers their growth. Our aim was to determine whether PD-L1 expression status correlates with prognosis in patients with advanced thoracic esophageal squamous cell carcinoma. Patients and Methods: The PD-L1 expression status of 177 patients treated with esophagectomy without preoperative therapy was evaluated immunohistochemically using tissue microarray. We then statistically analyzed the relationships between PD-L1 expression status and clinicopathological features and survival. Results: In patients undergoing surgery alone, PD-L1 expression was significantly positivity associated with a better prognosis. By contrast, there were no significant correlations between PD-L1 expression and clinicopathological features or outcomes in patients treated with surgery plus postoperative adjuvant chemotherapy. Conclusion: PD-L1 positivity in advanced thoracic esophageal squamous cell carcinoma may be predictive of a positive prognosis in patients treated without adjuvant chemotherapy.
引用
收藏
页码:1433 / 1441
页数:9
相关论文
共 50 条
  • [1] Surgery plus chemotherapy compared with surgery alone for localized squamous cell carcinoma of the thoracic esophagus: A Japan Clinical Oncology Group Study - JCOG9204
    Ando, N
    Iizuka, T
    Ide, H
    Ishida, K
    Shinoda, M
    Nishimaki, T
    Takiyama, W
    Watanabe, H
    Isono, K
    Aoyama, N
    Makuuchi, H
    Tanaka, O
    Yamana, H
    Ikeuchi, S
    Kabuto, T
    Nagai, K
    Shimoda, Y
    Kinjo, Y
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (24) : 4592 - 4596
  • [2] A Randomized Trial Comparing Postoperative Adjuvant Chemotherapy with Cisplatin and 5-Fluorouracil Versus Preoperative Chemotherapy for Localized Advanced Squamous Cell Carcinoma of the Thoracic Esophagus (JCOG9907)
    Ando, Nobutoshi
    Kato, Hoichi
    Igaki, Hiroyasu
    Shinoda, Masayuki
    Ozawa, Soji
    Shimizu, Hideaki
    Nakamura, Tsutomu
    Yabusaki, Hiroshi
    Aoyama, Norio
    Kurita, Akira
    Ikeda, Kenichiro
    Kanda, Tatsuo
    Tsujinaka, Toshimasa
    Nakamura, Kenichi
    Fukuda, Haruhiko
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2012, 19 (01) : 68 - 74
  • [3] [Anonymous], ESOPHAGUS, DOI DOI 10.1007/s10388-016-0531-y
  • [4] Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer
    Brahmer, Julie R.
    Tykodi, Scott S.
    Chow, Laura Q. M.
    Hwu, Wen-Jen
    Topalian, Suzanne L.
    Hwu, Patrick
    Drake, Charles G.
    Camacho, Luis H.
    Kauh, John
    Odunsi, Kunle
    Pitot, Henry C.
    Hamid, Omid
    Bhatia, Shailender
    Martins, Renato
    Eaton, Keith
    Chen, Shuming
    Salay, Theresa M.
    Alaparthy, Suresh
    Grosso, Joseph F.
    Korman, Alan J.
    Parker, Susan M.
    Agrawal, Shruti
    Goldberg, Stacie M.
    Pardoll, Drew M.
    Gupta, Ashok
    Wigginton, Jon M.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (26) : 2455 - 2465
  • [5] Prognostic significance of programmed death-1 and programmed death-ligand 1 expression in patients with esophageal squamous cell carcinoma
    Chen, Kaiyan
    Cheng, Guoping
    Zhang, Fanrong
    Zhang, Nan
    Li, Dan
    Jin, Jiaoyue
    Wu, Junzhou
    Ying, Lisha
    Mao, Weimin
    Su, Dan
    [J]. ONCOTARGET, 2016, 7 (21) : 30772 - 30780
  • [6] Chen LJ, 2014, INT J CLIN EXP PATHO, V7, P6015
  • [7] Cho Y, 2003, CANCER RES, V63, P1555
  • [8] Clemente CG, 1996, CANCER, V77, P1303, DOI 10.1002/(SICI)1097-0142(19960401)77:7<1303::AID-CNCR12>3.3.CO
  • [9] 2-0
  • [10] Chemoradiotherapy of locally advanced esophageal cancer - Long-term follow-up of a prospective randomized trial (RTOG 85-01)
    Cooper, JS
    Guo, MD
    Herskovic, A
    Macdonald, JS
    Martenson, JA
    Al-Sarraf, M
    Byhardt, R
    Russell, AH
    Beitler, JJ
    Spencer, S
    Asbell, SO
    Graham, MV
    Leichman, LL
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 281 (17): : 1623 - 1627